HMGB2 and esophageal squamous cell carcinoma: Second, considering that PD-1/PD-L1 immune checkpoint inhibitors are already widely used in ESCC, targeting HMGB2 in combination with checkpoint blockade may exert synergistic effects, thereby further enhancing NK cell–mediated antitumor activity.